Clinical Trial Update: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission [Phase 2]

View source ↗

Summary

Phase 2 trial update of an allogeneic GM-CSF vaccine with lenalidomide in multiple myeloma patients in complete or near complete remission. The study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Allogeneic Myeloma GM-CSF Vaccine (GM-CSF vaccine)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2025-08-27